key: cord-0843486-rvhgcegi
authors: Declercq, Jozefien; Tobback, Els; Vanhee, Stijn; De Ruyck, Natalie; Gerlo, Sarah; Gevaert, Philippe; Vandekerckhove, Linos
title: COVID‐19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies
date: 2021-09-29
journal: Allergy
DOI: 10.1111/all.15101
sha: 6ea209c32445158c070093884cae30ce1129cae7
doc_id: 843486
cord_uid: rvhgcegi

nan

To the editor, To date, several vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) have proven to effectively reduce severe illness. 1, 2 To promote herd immunity and reduce virus circulation, vaccines need to effectively reduce transmission risk. The nasal cavity is the first entrance point for SARS-CoV-2, and it has been suggested that viral replication is most efficient in the upper airways. Forty-six subjects, mainly females, were included in the study (Table 1) 

Additional supporting information may be found in the online version of the article at the publisher's website.

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Study on the mucosal and serological immune response to the novel coronavirus (SARS-CoV-2) vaccines

Reliable mite-specific IgE testing in nasal secretions by means of allergen microarray

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction